Project/Area Number |
21590589
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | University of Toyama |
Principal Investigator |
YAMAMOTO Seiji 富山大学, 大学院・医学薬学研究部(医学), 助教 (10456361)
|
Co-Investigator(Kenkyū-buntansha) |
HATTORI Yuichi 富山大学, 大学院・医学薬学研究部(医学), 教授 (50156361)
長井 良憲 富山大学, 大学院・医学薬学研究部(医学), 准教授 (30431761)
|
Co-Investigator(Renkei-kenkyūsha) |
NAGAI Yoshinori 富山大学, 大学院・医学薬学研究部(医学), 准教授 (30431761)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
Keywords | 薬物治療学 / 組織再生 / 骨髄由来多能性前駆細胞 / 再生医療 / 炎症 |
Research Abstract |
In systemic inflammatory response syndrome, myeloblasts are observed in injured lung. To elucidate, whether pluripotent progenitor cells(myeloblasts) differentiate to alveolar type II cells or support to survive of the alveolar cells in sepsis. We demonstrated that pluripotent progenitors were classified 2 subsets by CD34 expression. Although CD34^+subset showed strong phagocytic activity, CD34^-subset may have alveo-protective effect.
|